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Stlmmnry 
Sj6gren's syndrome (SS) is a chronic autoimmune disorder characterized by lymphocytic infiltration 
of the salivary  and lacrimal glands. These patients have a markedly increased frequency of developing 
non-Hodgkin's lymphoma in their salivary glands and cervical lymph nodes. Translocations of 
proto-oncogene bd-2 t(14;18) were observed in five of seven SS-associated lymphomas by Southern 
blot analysis. Using primers  specific for chromosomes 14 and 18, translocation  of the proto- 
oncogene bcl-2 was detected by polymerase chain reaction (PCR) in all five lymphomas positive 
by Southern blot analysis. Among SS patients lacking clinical evidence of coexistent lymphoma, 
no bcl-2 translocations  were detected in 50 consecutive salivary gland biopsies. Of particular 
interest,  pre-lymphoma biopsies were available from the seven SS patients  who subsequently 
developed lymphoma and these DNA samples lacked detectable t(14;18) translocations even though 
they exhibited  oligoclonal rearrangements of their immunoglobulin genes. We conclude that 
the great sensitivity of PCR can help us in detecting early onset of lymphoma in SS patients 
and aid in understanding the transition from autoimmunity to lymphoma. 
p atients with the autoimmune disease Sj6gren's syndrome 
are at markedly increased  risk of developing non-Hodgkin's 
B cell lymphoma involving the lacrimal and salivary glands 
(1). The steps involved in the transition from autoimmunity 
to B cell neoplasia are not well understood. It has been pro- 
posed that lymphomagenesis is a multistep process involving 
sequential activation of proto-oncogenes by translocations or 
mutations that alter normal cellular regulatory functions (2-4). 
Among B cell lymphomas, the most common translocation 
involves the bcl-2 oncogene in a t(14;18) translocation  (Fig. 
1) (5, 6). The breakpoints  are remarkably focused on chro- 
mosome 18, where •60%  duster at what is called major 
breakpoint region (mbr) 1 and up to 25% at minor duster 
region (mcr) (7, 8) (Fig.  1). These translocations  result in 
the deregulated expression of the bcl-2 gene and synthesis 
of inappropriately  high levels of bcl-2 protein (9, 10). Gene 
transfer studies suggest a role for bcl-2 in cell survival, growth 
enhancement, and oncogenic transformation  (11). DNA se- 
quence analysis ofbcl-2 translocations has suggested that these 
alterations may have occurred as a result of naturally occur- 
ring double-stranded DNA breaks with N-segment addition, 
repair, and ligation of the derivative 14th and 18th chromo- 
somes (12). The particular location in the body where B cells 
undergo bcl-2 translocation  remains unclear. Bakhshi et al. 
(12) suggested  that bcl-2 translocation  occurs in the bone 
1 Abbreviations used in tkispaper: mbr, major breakpoint region; mcr, minor 
cluster region; SS, Sj6gren's Syndrome. 
marrow during the early stages of B cell development, while 
Cotter et al. (13) have demonstrated bcl-2 translocation  at 
a later stage of B cell development after V-D-J joining. Our 
finding of bcl-2 translocations in salivary gland lymphomas 
of patients  with Sj6gren's syndrome provided an opportu- 
nity to examine their prelymphoma biopsies to see if such 
translocation  preceded the emergence of overt lymphoma. 
Sj6gren's Syndrome (SS) is characterized by lymphocytic 
infiltration of salivary and lacrimal glands, hypergammaglobu- 
linemia, and high levels of circulating autoantibodies including 
rheumatoid factor and antinuclear  antibodies  (14-16).  Al- 
though the majority of lymphocytes infiltrating these glands 
are CD4 + T  cells (17), these patients  develop B cell lym- 
phomas (18) with a frequency >40-fold over age- and sex- 
matched controls (1). Further,  the lymphomas arise almost 
exclusively in the salivary glands and cervical lymph nodes, 
which are the site of autoimmune inflammation in SS pa- 
tients and are an unusual site of lymphoma presentation  in 
patients  lacking SS (19). Before developing lymphoma, SS 
patients have recurrent swelling of the salivary gland, which 
exhibits a "pre-lymphoma" or "myo-epithelial" lesion on bi- 
opsy (20, 21). Lymphocytes eluted from these pre-lymphoma 
biopsies are predominantly polyclonal T cells (17), and con- 
tain a small percentage of B cells that exhibit detectable clonal 
rearrangements of their heavy and light chain genes (21, 22). 
This has led to a discussion about whether these myoepithelial 
lesions are autoimmune or actually represent an early "lym- 
phoma in situ" (23-25). 
If rare "lymphoma in situ" cells were present  in a pre- 
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translocations that are detected in the subsequent lymphoma. 
This possibility is shown schematically in Fig.  2 A,  where 
rare "lymphoma cells" subsequently undergo clonal expan- 
sion to become an overt lymphoma. To test this hypothesis, 
we examined pre-lymphoma biopsies from five SS patients 
whose subsequent lymphoma contained t(14;18)  transloca- 
tions detectable by PCR. The great sensitivity of PCR would 
make possible detection of rare cells bearing the transloca- 
tion. Of importance,  each of these pre-lymphoma SS biop- 
sies previously has been shown to contain oligoclonal rear- 
rangements of heavy and light chain Ig genes (22), and thus 
it is possible to determine whether bcl-2 translocation is de- 
tectable at the time of oligoclonal expansion of B-cells.  An 
alternative  hypothesis (Fig 2 B) is that  the pre-lymphoma 
salivary  gland does not contain B cells with karyotypic ab- 
normalities  and that  oligoclonal B cell expansion  precedes 
karyotypic translocation.  Among the five SS pre-lymphoma 
biopsies, we did not find bcl-2 translocations.  These results 
suggest that lymphoma develops in SS patients as a muhistep 
process where oligoclonal B-cell expansion precedes t(14;18) 
translocation. 
Materials  and Methods 
Patients with SS were seen at Scripps Clinic and Research Foun- 
dation (La Jolla, CA). All patients had definite SS with keratocon- 
junctivitis sicca, xerostomia, class 4-positive minor salivary gland 
biopsies, autoantibodies  including  rheumatoid  factor and ANA 
(titers >640),  and the presence of anti-SS-A/SS-B antibodies (15, 
26). Among 200 SS patients followed for >5 yr, 14 developed non- 
Hodgkin's  lymphoma involving cervical lymph node or salivary 
gland. The time interval between initial diagnosis of SS and the 
appearance of lymphoma was at least 3 yr. All lymphomas were 
B cell based on immunohistological  study and Southern blot anal- 
ysis of DNA for heavy and light chain rearrangement  (22). 13 of 
14 lymphomas were IgM-K and one lymphoma was IgA-A. In seven 
of these patients, previous biopsies of major salivary  glands or lymph 
nodes had been performed and showed "reactive" changes but not 
overt lymphoma  (17); therefore, these biopsies are referred to as 
"pre-lymphoma". Bone marrow aspirates from iliac crest were avail- 
able from these seven patients. In two cases, combination chemo- 
therapy was unsuccessful and patients died of septicemia; complete 
autopsy tissue was analyzed including thoracic and abdominal lym- 
phoid  tissues. 
DNA was examined from other tissues including minor salivary 
gland biopsies from 50 consecutive SS patients who had no clinical 
evidence of lymphoma,  30 minor salivary gland biopsies from pa- 
tients lacking autoimmune disease, 10 salivary gland biopsies from 
patients with benign adenoma or adenocarcinoma, 10 lymph node 
biopsies from patients with systemic lupus erythematous, 10 lymph 
node biopsies from patients with rheumatoid arthritis,  10 tonsillar 
lymph node biopsies from immunologically normal individuals, and 
seven lymph node biopsies containing "follicular" non-Hodgkin's 
lymphoma. 
Genomic Southern Blot Analysis.  Procedures for extraction  of 
DNA from tissues and cell lines, Southern blot analysis of DNA, 
and radiolabeling of probes have been described (22, 27). High mo- 
lecular  weight  DNA  was digested  with  HindIII  according  to 
manufacturers instruction  (New England Biolab, Beverly, MA). 
Chromosome 18-specific probes pFD1 and pFL-2, detecting mbr 
and mcr, respectively (Fig. 1) (7, 28), were obtained from Dr. M. 
Cleary (Stanford University, Stanford, CA). 
A B cell line lymphoma, SU-DHL6, containing known translo- 
cation t(14;18) involving mbr region was obtained from Dr. Allan 
Epstein  (University  of Southern  California,  Los Angeles, CA). 
Samples oflymphoma tissue from a patient with known transloca- 
tion t(14;18) involving mcr region was obtained from Dr. M. Cleary 
(Stanford University, Stanford, CA). 
Polymerase Chain Reaction.  Amplification of DNA involving 
bcl-2 translocation was performed by PCR using a oligonucleo- 
tide primer specific for a consensus sequence of Ig heavy chain J 
segment and a primer specific  for mbr or a mcr (29, 30). The PCR 
assay was performed with a DNA Thermal Cycler (Cetus Corp., 
Emeryville, CA), using 1 #g DNA, 100 pmol of each primer, 2.0 
mM MgCI~, 20 nmol of each dNTP, 2.5 U Taq polymerase (Cetus 
Corp.), and 35 cycles of amplification. One-tenth of the amplified 
product was electrophoretically separated in 1.6% agarose gel and 
transferred by alkaline blot method onto nylon membranes, which 
were hybridized with a 32p end-labeled oligonucleotide  probe at 
42~  for  16 h.  Autoradiography  was performed  for 4-24 h  at 
-80~  using X-Omat AR film (Eastman Kodak Co., Rochester, 
NY) with a single intensifying  screen. 
Results 
To demonstrate the sensitivity and specificity of the PCR 
reaction for bcl-2 t(14;18)  translocations involving the mbr 
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Figure 1.  Schematic  representation of chromosome 18 and 14. (~P) 
The location of the mbr and the mcr on chromosome 18. Solid boxes 
represent transcriptional units of the bcl-2 gene. pFI#l and pFb2 are chro- 
mosome 18-specific  DNA probes. (Middle) The germline configuration 
of the Ig heavy  chain allele on chromosome 14. (Bottom) The rearranged 
Ig heavy chain gene in a lymphoma with a t(14;18) translocation. 
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Figure  2.  Schematic models for development oflymphoma in Sj6gren's 
Syndrome (.4) It is possible that rare B cells containing a bcl-2 transloca- 
tion are present in the salivary gland biopsy of SS patients. An overt lym- 
phoma results when this karyotypically  abnormal B cell escapes T cell sur- 
veillance and clonally expands  into a non-Hodgkin's lymphoma. (B) An 
alternate possibility  is that karyotypically  abnormal B cells are not present 
at a detectable level in SS biopsies, even though clonal expression of sali- 
vary gland B cells can be demonstrated by clonal Ig rearrangements.  Per- 
sistent B cell division in the SS salivary gland may lead to increased chance 
of karyotypic error associated with lymphoma development. 
region, DNA from the lymphoma cell line SU-DHL-6 was 
mixed with  normal  genomic human DNA  before  PCR 
amplification. Using a 4-h autoradiogram (Fig. 3 A),  10 -s 
/~g of SU-DHL-6 DNA easily could be detected in a mixture 
containing 1/zg of normal DNA.  This corresponds to ap- 
proximately one cell translocation  per 1@ of uninfected cells. 
Fig. 3 B shows a similar reconstitution experiment using lym- 
phoma DNA that exhibits t(14;18) translocation involving 
mcr segment. 
DNA from seven SS lymphomas was analyzed and a bcl-2 
translocation involving the mbr region was detected in three 
of seven patients by PCR methods (Fig.  4, lanes 6, 8,  and 
10). In comparison, lanes I  and 2 are negative controls, and 
lane 3 contains DNA from a cell line (SU-DHL6) with known 
mbr t(14;18) translocation. In pre-lymphoma biopsies from 
each SS patient, mbr translocations were not detectable (Fig. 
4,  lanes 5,  7,  and 9). 
DNA from SS lymphomas with breakpoints in the mcr 
of chromosome 18 is shown in Fig.  5,  lanes 6, 8, and I0. 
Again, the prelymphoma biopsies from SS patients did not 
demonstrate any detectable mcr translocation (Fig.  5, lanes 
5, 7, and 9). One patient (SS-1) showed translocations with 
both mbr and mcr breakpoints on chromosome 18 (Fig. 4, 
lane 6;  Fig.  5,  lane 10).  To rule out the possibility that a 
negative result in some patient samples was due to inefficiency 
or complete failure of the PCR reaction, a single copy gene 
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Figure 3.  Southern blot analysis of PCR amplified t(14;18) transloca- 
tions demonstrating the PCR sensitivity.  1/~g of DNA was amplified 
using oligonucleotide  primers specific for mbr (,4) or for mcr (B) and heavy 
chain J segment. After 35 cycles of PCR, the amplification product was 
separated on agarose gel and probed with 32p-labeled probe to the mbr 
or mcr regions. (A) Lymphoma DNA containing mbr translocation.  (Lane 
6) 0.1/~g of SU-DHL6 DNA was added to 1/~g of normal donor DNA. 
(Lanes 2-5). Serial 10-fold dilutions of SU-DHL6 DNA were added to 
1/~g of normal donor DNA before PCR amplification. Lane I  contains 
DNA from a follicular lymphoma with a mcr translocation. The size of 
the mbr amplification  product is 234 bp. (B) Serial dilutions of DNA from 
a lymphoma with a known mcr-breakpoint in normal donor DNA in lanes 
2-6. Lane 6 contains 0.1/xg lymphoma DNA mixed with 1/zg normal 
genomic DNA. All autoradiographs were exposed for 4 h.  The size of 
the amplification product for this mcr lymphoma was 603  bp. 
(HLA-DQo  0 was successfully amplified in all samples (data 
not shown). 
To confirm the PCR results and to search for additional 
t(14;18) translocations that may not be detected by PCR, DNA 
from each of the lymphomas was digested with restriction 
enzyme HindIII and hybridized with PFL-1 and PFL-2 probes 
to mbr and mcr regions, respectively  (Fig.  6).  The results 
of restriction fragment length analysis using PFIA and PFb2 
probes were in correlation with the PCR results, and no ad- 
ditional SS lymphoma with bcl-2 translocation was detected. 
Fig. 6, A shows representative Southern blots from lymphomas 
with mer translocation (lanes 4 and 6) and the absence of Figure 4.  Southern blot analysis of PCR. amplified mbr t(14;18) break- 
points in SS lymphomas.  DNA from pre-lymphoma (PL) and lymphoma 
(L) salivary gland biopsies were subjected  to PCR using a mbr-speciiic 
primer and a J, primer.  (Lane I) PCP, reaction mixture without DNA 
template;  (lane 2) control DNA without t(14;18);  (lane 3) SU-DHL-6, 
cell line with mbr t(14;18); (lane 4) patient DNA with known mcr t(14;18); 
(lane 5) SS-1, PL;  (lane 6) SS-1, L; (lane 7) SS-2, PL; (lane 8) SS-2, L; 
(lane 9) SS-3, PL;  (lane 10) SS-3, L. 
Figure 5.  Southern blot analysis of PCR.-amplified mcr t(14;18) break- 
points in SS lymphomas. DNA from pre-lymphoma [PL] and lymphoma 
[L] salivary gland biopsies  were subjected  to PCR. using a tact-specific 
primer in conjunction with a J. primer.  (Lanes I  and 2) Negative con- 
trois as in Fig. 3; (lane 3) SU-DHL-6,  cell line with mbr t(14;18); (lane 
4) non-SS Lymphoma patient DNA with known mcr t(14;18) transloca- 
tion; (lane 5) SS-4, PL; (lane 6) SS-4, L; (lane 7) SS-5, PL; (lane 8) SS-5, 
L; (lane 9) SS-1, PL;  (lane I0) SS-1, L. 
translocation  in the pre-lymphoma biopsies (lanes 3 and 5). 
Similarly, Fig. 6 B shows mcr translocation  in a lymphoma 
from a SS patient (lane 4). Of particular interest, patient SS-1, 
who exhibited both mcr and mbr translocations using PCR, 
had detectable bcl-2 rearrangement on Southern blot only 
with mcr probe pFb2  (Fig. 6 A, lane 6). 
Finally, DNA from salivary gland and lymph node tissues 
of normals, patients with autoimmune disease, and patients 
with solid tumors was studied.  These included minor sali- 
vary gland biopsies from 50 SS patients lacking lymphoma, 
10 lymph nodes from patients with rheumatoid arthritis or 
systemic lupus erythematous, and 10 adenocarcinoma  sali- 
vary gland tumors. These DNA samples did not exhibit de- 
tectable bd-2 translocation  by PCR analysis. 
Discussion 
Patients with SS have increased risk of developing lym- 
phoma involving the cervical lymph nodes and salivary glands 
(1). We now show that five of seven of these tumors had 
bcl-2 t(14;18) translocations.  From a clinical and histologic 
point of view, it is often difficult to distinguish "pseudolym- 
phoma" (pre-lymphoma)  in SS patients  from definite non- 
Hodgkin's lymphoma (21, 22, 31). Therefore, analysis  ofbd-2 
translocations in tissue biopsies will aid diagnosis. Since only 
a small amount of tissue is required for PCR analysis, diag- 
nostic samples may be obtained by percutaneous biopsy or fine 
needle aspiration. This is in contrast  to the current need for 
an open surgical biopsy to remove enlarged salivary glands 
Figure  6.  Southern  blot  analysis of 
t(14;18)  translocations.  Genomic  DNA 
from SS patients and from lymphomas with 
known t(14;18) translocations were digested 
with HindlII, electrophoreticaily separated 
in 0.7% agarose, transferred to nylon filters, 
and subsequently hybridized with the mbr- 
specific probe pFbl (.4) or the mcr-specific 
probe pFb2  (B).  The germline HindlII 
bands containing pFL-I and pFD2, respec- 
tively, corresponds  to 4.3 and 17 kb.  (A) 
Detection of mcr t(14;18). (Lane I) DNA 
with known mcr t(14;18); (lane 2) control 
DNA; (lane 3) SS-5, pre-lymphoma biopsy; 
(lane  4) SS-5, lymphoma;  (lane  5)  SS-1, 
pre-lymphoma biopsy;  (lane 6) SS-1, lym- 
phoma.  (B)  Detection  of mbr  t(14;18). 
(Lane  1)  SU-DHL-6;  (lane  2)  Control 
DNA;  (lane  3)  SS-2, pre-lymphoma bi- 
opsy;  (lane  4)  SS-2, lymphoma;  (lane 
5)  SS-1, pre-lymphoma biopsy;  (lane  6) 
SS-1, lymphoma. 
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tive result (i.e., no detectable translocation) would not elimi- 
nate the diagnosis of lymphoma, but a positive finding would 
alert the internist and surgeon to the increased chance oflym- 
phoma. It has recently been reported that patients with B 
cell lymphomas with t(14;18)  translocations have a poorer 
response to therapy (32). Therefore, detection ofbcl-2 trans- 
location at the earliest stage would give more opportunities 
for clinical intervention to prevent lymphoma progression. 
The finding of bcl-2 translocation in SS lymphomas also 
helps clarify the steps  in transition from autoimmunity to 
lymphoproliferation.  At  the  stage  of pre-lymphoma,  the 
majority of lymphocytes infiltrating the salivary gland are 
polyclonal T cells (17). However, 15-20%  of these salivary 
gland lymphocytes are B cells that express follicular B cell- 
associated antigens (33),  exhibit oligoclonal rearrangements 
of their Ig genes (22),  and have an increased proportion of 
cells undergoing DNA replication (17).  The present study 
demonstrates that these pre-lymphoma B cells lack detect- 
able bcl-2 translocations. We propose that these B cells un- 
dergo cell division as a result of stimulation by activated T 
cells,  their growth factors, and/or autoantigen. As a result 
of the cell division within the salivary gland, the B cells have 
increased opportunity for bcl-2 translocation and resulting 
lymphoma. Other factors that may contribute to lymphoma- 
genesis in SS patients may include the high levels of growth 
factors produced in the salivary gland (34) and Epstein-Barr 
virus that has latency at this site (35,  36). 
The lymphomas in SS patients occur predominantly in the 
salivary glands and therefore we favor the occurrence of the 
bcl-2 translocations at this peripheral site. This is in contrast 
to the hypothesis of Bakhshi et al. (12), who suggested that 
bcl-2 translocations could occur only among pre-B cells in 
the bone marrow. Although we can not rule out that the 
translocation first occurred in the marrow and the neoplastic 
cells subsequently migrated to the salivary glands, this possi- 
bility seems less likely since lymphomatous cells were not 
detected at other lymphoid sites such as abdominal lymph 
nodes, spleen, or bone marrow in SS lymphoma patients where 
autopsy was performed. Also, it remains possible that rare 
circulating pre-B cells underwent bd-2 translocation within 
the microenvironment of the salivary gland. However, Cotter 
et al. (13) have demonstrated bcl-2 translocations among ma- 
ture B cells in tissue culture, and our results suggest that 
a similar process has occurred in vivo at an inflammatory site. 
Surprisingly, one patient's lymphoma contained both an 
mbr and an mcr translocation using PCR. Based on Southern 
blot analysis, the proportion of cells that contained the mcr 
translocation was much higher than the proportion of cells 
with the mbr translocation. It is not yet possible to deter- 
mine whether the mbr translocation occurred in a cell with 
a prior mcr alteration or on a distinct B cell. However, DNA 
sequence analysis of these bcl-2 translocations is in progress 
to clarify the basis  of this unusual finding. 
In conclusion, our results demonstrate the presence of bcl-2 
translocations in non-Hodgkin's lymphoma occurring in SS 
patients. These translocations were not detected in the pre- 
lymphoma biopsies from the same patients. Thus, detection 
of blc-2 translocations may aid in improved early detection 
of lymphoma and improved treatment of SS patients. Although 
the function of the bcl-2 gene product is not yet clear (37, 
38), the translocationjuxtaposes the bcl-2 gene with Ig heavy 
chain locus, increases B cell survival, and may lead to increased 
chance of neoplastic transformation (11, 28,  29,  39,  40). 
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